KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $31.2 million.

  • Halozyme Therapeutics' Other Gross PP&E Adjustments rose 2211.31% to $31.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $31.2 million, marking a year-over-year increase of 2211.31%. This contributed to the annual value of $31.2 million for FY2025, which is 2211.31% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Other Gross PP&E Adjustments is $31.2 million, which was up 2211.31% from $38.7 million recorded in Q3 2025.
  • Halozyme Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at $39.4 million during Q3 2022, with a 5-year trough of $5.2 million in Q4 2022.
  • Over the past 5 years, Halozyme Therapeutics' median Other Gross PP&E Adjustments value was $21.3 million (recorded in 2022), while the average stood at $22.9 million.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Other Gross PP&E Adjustments showed a top increase of 14928.68% in 2023 and a maximum decrease of 6850.94% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Gross PP&E Adjustments stood at $15.2 million in 2021, then plummeted by 65.84% to $5.2 million in 2022, then surged by 149.29% to $12.9 million in 2023, then skyrocketed by 97.6% to $25.6 million in 2024, then increased by 22.11% to $31.2 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $31.2 million for Q4 2025, versus $38.7 million for Q3 2025 and $32.9 million for Q2 2025.